and rarely survival beyond 2 years regardless of treatment modality. [2] [3] [4] The optimal treatment approach for PLS is not well defined.
Surgery is the only treatment modality that can offer a potential cure.
However, existing studies of outcomes after resection of liver sarcomas are limited by small patient numbers treated over extended periods of time. 5, 6 Amongst patients who undergo surgery, the indications for resection versus transplantation are not defined.
Moreover, the benefit of adjuvant treatment remains questionable with existing literature reporting minimal if any benefit. 2 In an effort to circumvent the above limitations, we examined the National Cancer Database, as it captures approximately 70% of new cancer cases treated nationwide with detailed clinicopathologic and treatment data. 7 The aims of the present study were to determine outcomes after resection of PLS, utilizing a large contemporary cohort, to examine whether transplantation is associated with an improvement in survival over resection, and to determine whether adjuvant treatment is associated with an improved outcome. 3 | RESULTS
| MATERIALS AND METHODS

| Clinicopathologic characteristics
During the period 2004-2014, we identified 237 patients who underwent liver resection for a primary liver sarcoma or carcinosarcoma. The majority of patients were female (60.8%) and white (81%) with a Charlson comorbidity index of 0 (76.8%). Median age was 52 years. Table 1 illustrates the clinicopathologic data of this cohort.
The most common histologies were epithelioid hemangioendothelioma (28.3%), and angiosarcoma (27%). Lobectomies or extended lobectomies were performed in 40.9% of patients, whereas liver transplantation was performed in 17.3% of patients, almost exclusively
| Angiosarcomas and epithelioid hemangioendotheliomas: resection versus transplantation
We examined separately the 131 patients with angiosarcoma and epithelioid hemangioendothelioma who underwent resection or transplantation. Table 2 illustrates the clinicopathologic characteristics of these patients. Patients who underwent transplantation were younger, had larger tumors, and more frequent nodal disease.
Overall median survival was similar for resection versus transplantation for angiosarcomas and epithelioid hemangioendotheliomas ( Figure 2 ). When they were examined separately, angiosarcomas had a trend for improved survival with resection versus transplantation (median OS: 16.6 vs 6 mo, respectively; P = 0.04) whereas epithelioid hemangioendotheliomas had similar great outcomes (median OS not reached for either group; P = 0.3).
Well-differentiated tumors were associated with improved survival over moderately/poorly differentiated for angiosarcomas (median OS: not reached vs 8.6 mo; P = 0.02), with a trend for improved survival for epithelioid hemangioendotheliomas (97.5 vs 56.6 mo; The outcomes of resection and transplantation for hepatic epithelioid hemangioendotheliomas (HEHE) and hepatic angiosarcomas (HAS) appear to be similar however transplanted patients had more advanced disease. Angiosarcomas and carcinosarcomas were associated with overall survival of less than a year which should be taken into account in considering resection for these patients. Chemotherapy was not associated with improved outcome.
Previous reports on the outcomes of surgical resection for PLS are limited by a small number of patients treated over extended periods of time, during which major changes in liver surgery occurred. Liver transplantation (LT) should be used with caution in PLS.
Almost all LT in the current study occurred for HEHE and HAS.
However, survival benefit of transplantation over resection was not shown for either histology in this analysis. A major limitation of this comparison is that transplantation was utilized for larger tumors with frequent nodal spread, the volume of disease was therefore different. 11 However, the data collection, validation and reporting process for the NCDB is standardized, monitored, and reviewed. 7 The liver module includes only patients who underwent liver resection for a primary liver neoplasm; however, liver invasion from a retroperitoneal sarcoma necessitating hepatectomy cannot be excluded. Data on specific chemotherapy agents and treatment of recurrent disease are lacking.
Survival is measured as overall survival rather than disease-specific survival. Comorbidity is assessed with the Charlson comorbidity index, however the exact nature of the comorbid conditions is not known, which may affect the decision for surgery. The study is further limited by small sample size in some histologic subgroups, which makes producing meaningful results very difficult. Despite these weaknesses, the NCDB provides a substantial amount of clinicopathologic, oncologic, and treatment data. This relatively large, contemporary cohort is reflective of practice patterns in the United States. Given the rarity of this disease, NCDB and other population-based data sets are an excellent adjunct to small scale institutional data. Moreover, the data in this study will be invaluable in counseling liver sarcoma patients with regards to expectations and outcomes.
| CONCLUSIONS
In conclusion, the current study suggests that surgical resection represents the mainstay of treatment for primary liver sarcomas.
Survival is closely related to the histologic subtype. Transplantation should be utilized with caution as it does not improve the dismal prognosis of angiosarcomas and it might not provide additional benefit to resection for epithelioid hemangioendotheliomas.
